ASMS and Huwel Launch Cubo RT-PCR Platform for Point-of-Care Diagnostics
Avio Smart Market Stack Limited and Huwel Lifesciences have officially launched Cubo, a revolutionary ultra-compact RT-PCR platform designed to expand molecular diagnostics access across India and global markets. The point-of-care solution supports comprehensive testing applications including tuberculosis, respiratory infections, and viral panels, targeting deployment in rural clinics, district hospitals, and remote healthcare facilities.

*this image is generated using AI for illustrative purposes only.
Avio Smart Market Stack Limited (formerly Bartronics India Limited) and Huwel Lifesciences have officially launched Cubo, an ultra-compact RT-PCR platform designed to revolutionize molecular diagnostics access across India and global healthcare systems. The announcement, made through a regulatory filing under Regulation 30 of SEBI (LODR) Regulations, 2015, marks a significant advancement in the companies' strategic partnership for healthcare technology expansion.
Revolutionary Point-of-Care Platform
Cubo represents a breakthrough in decentralized healthcare, combining laboratory-grade RT-PCR capabilities with a highly portable, cost-efficient deployment model. The platform enables advanced molecular testing within a compact form factor that can be deployed far beyond traditional laboratory environments, addressing critical gaps in healthcare access.
| Platform Feature: | Capability |
|---|---|
| Technology: | Ultra-compact RT-PCR |
| Deployment: | Point-of-care molecular diagnostics |
| Target Markets: | Rural clinics, district hospitals, mobile health units |
| User Interface: | Simplified workflow, intuitive design |
| Testing Menu: | Multi-assay capability |
Comprehensive Testing Applications
The platform supports a wide range of diagnostic applications, positioning it as a versatile solution for diverse healthcare needs. Cubo's testing menu includes tuberculosis, respiratory infections, influenza, viral panels, women's health diagnostics, sexually transmitted infections, fever panels, and future outbreak-response applications.
Strategic Market Positioning
Positioned as a first-of-its-kind indigenous innovation, Cubo addresses the challenge of diagnostic samples traveling long distances to centralized facilities, which often results in delays and logistical inefficiencies. The platform enables accurate RT-PCR testing at or near the point of care, reducing turnaround times and operational complexity while supporting the global shift toward localized diagnostic models.
Leadership Vision
Commenting on the product launch, Vidhya Sagar Reddy, Managing Director of ASMS, stated: "Healthcare access should not be determined by geography. Cubo represents a major step toward bringing advanced diagnostics directly into underserved markets at scale." Shesheer Kumar, Managing Director of Huwel Lifesciences, added: "Cubo has been engineered to combine scientific precision with operational simplicity. Early leadership in compact molecular diagnostics can translate into sustained long-term market strength."
Market Impact and Future Outlook
The launch builds upon the companies' earlier announced strategic partnership for Southeast Asia expansion, strengthening ASMS's emerging healthtech vertical alongside its existing focus areas in financial inclusion and agritech initiatives. With its affordability, portability, and wide deployment potential across rural clinics, district hospitals, mobile health units, industrial sites, border areas, and remote regions, Cubo is expected to establish a strong competitive advantage in the rapidly growing molecular diagnostics market.
Historical Stock Returns for Bartronics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.40% | -1.71% | -4.60% | -36.21% | -49.93% | -43.41% |
What regulatory approvals will Cubo need to secure for deployment across different international markets beyond India?
How will the pricing strategy for Cubo compare to existing centralized RT-PCR testing models in rural healthcare markets?
Which specific Southeast Asian countries are likely to be the first targets for Cubo's international expansion?


































